3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
8
Gastro-enteropancreatic neuroendocrine tumor
7
Sarcoma
6
Carcinoid Tumor
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Paraganglioma
5
Neoplasms
5
Prostatic Neoplasms
4
Pheochromocytoma
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
4
Thyroid Neoplasms
3
Neuroblastoma
3
Carcinoma, Renal Cell
3
Thyroid Diseases
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Meningioma
2
Medulloblastoma
2
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Tertiary Lymphoid Structures
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled